DaVita (DVA) 10-K risk factor changes: FY2020 vs FY2019

*This Annual Report on Form 10-K contains forward-looking statements within the meaning of the federal securities laws.

Please read the cautionary notice regarding forward-looking statements in Item 7 of Part II of this Annual Report on Form 10-K under the heading “Management’s Discussion and Analysis of Financial Condition and Results of Operations.” These forward-looking statements involve risks and uncertainties, including those discussed below, which could have a material adverse effect on our business, cash flows, financial condition, results of operations and/or reputation.

The risks and uncertainties discussed below are not the only ones facing our business.

Additional risks and uncertainties not currently known to us or that we currently deem to be immaterial could also have a material adverse effect on our business, cash flows, financial condition, results of operations and/or reputation.*

Summary Risk Factors

The following is a summary of the principal risks and uncertainties that could adversely affect our business, cash flows, financial condition and/or results of operations, and these adverse impacts may be material.

This summary is qualified in its entirety by reference to the more detailed descriptions of the risks and uncertainties included in this Item 1A below and you should read this summary together with those more detailed descriptions.

These principal risk and uncertainties relate to, among other things:

*Risks Related to the Operation of our Business*

- the dynamic and evolving novel coronavirus pandemic;

- the complex set of governmental laws, regulations and other requirements that impact us, including potential changes thereto;

- the various lawsuits, demands, claims, *qui tam* suits, governmental investigations and audits and other legal matters that we may be subject to from time to time;

- our ability to comply with complex privacy and information security laws that impact us and/or our ability to properly maintain the integrity of our data, protect our proprietary rights to our systems or defend against cybersecurity attacks;

- our negotiations and arrangements with commercial payors, including with respect to value-based care and Medicare Advantage plans, the average rates that commercial payors pay us, any restrictions in plan designs or other contractual terms, including, without limitation, the scope and duration of coverage and in-network benefits;

- the number or percentage of our patients with higher-paying commercial insurance;

- our ability to successfully implement our strategy with respect to home-based dialysis;

- changes in the structure of and payment rates under government-based programs;

- changes in clinical practices, payment rates or regulations impacting pharmaceuticals;

- our ability to compete successfully, including, without limitation, implementing our growth strategy and/or retaining patients and physicians willing to serve as medical directors;

- our acquisitions, mergers, joint ventures or dispositions;

- our ability to establish and maintain supply relationships that meet our needs at cost-effective prices or at prices that allow for adequate reimbursement as applicable, as well as our ability to access new technology or superior products in a cost-effective manner;

- our ancillary services and strategic initiatives, including without limitation, our international operations and our ability to expand within markets or to new markets, or invest in new products or services;

- our ability to appropriately estimate the amount of dialysis revenues and related refund liabilities;

- changes in physician referrals to our dialysis centers, whether due to governmental laws, regulations or other requirements, new competition, a perceived decrease in the quality of service levels at our centers or other reasons;

- increases in labor costs, including, without limitation, due to shortages, changes in certification requirements and/or higher than normal turnover rates in skilled clinical personnel; or currently pending or future governmental laws, rules, regulations or initiatives;

- our ability to attract and retain key leadership talent;

- our ability to attract and retain employees or our ability to manage operating cost increase or productivity decreases whether due to union organizing activities or legislative or other changes;

- our ability to effectively maintain, operate or upgrade our information systems or those of third-party service providers upon which we rely, including, without limitation, our clinical, billing and collections systems;

*General Risks*

- our current or future level of indebtedness, including, without limitation, our ability to generate cash to service our indebtedness and for other intended purposes and our ability to maintain compliance with debt covenants;

- changes in tax laws, regulations and interpretations or challenges to our tax positions;

- liability claims for damages and other expenses that are not covered by insurance or exceed our existing insurance coverage;

- our ability to successfully maintain an effective internal control over financial reporting;

- deterioration in economic conditions, disruptions in the financial markets or the effects of natural or other disasters, political instability, public health crises or adverse weather events such as hurricanes, earthquakes, fires or flooding, including as such events may be impacted by the effects of climate change; and

- provisions in our organizational documents, our compensation programs and policies and certain requirements under Delaware law that may deter changes of control or make it more difficult for our stockholders to change the composition of our Board of Directors and take other corporate actions that our stockholders would otherwise determine to be in their best interests.

Risks Related to the Operation of our Business

We face various risks related to the dynamic and evolving novel coronavirus pandemic, any of which may have a material adverse impact on us.

The disease caused by the novel coronavirus (COVID-19) is impacting the world and our business in many different ways.

The ultimate impact of COVID-19 on us will depend on future developments that are highly uncertain and difficult to predict, including among other things, the severity and duration of the pandemic; further spread or resurgence of the virus, including as a result of the emergence of new strains of the virus; its impact on the chronic kidney disease (CKD) population and our patient population; the availability, acceptance, impact and efficacy of COVID-19 treatments, therapies and vaccines; the pandemic’s continuing impact on the U.S. and global economies and unemployment; the responses of our competitors to the pandemic and related changes in the marketplace; and the timing, scope and effectiveness of federal, state and local governmental responses.

The impact could come in many forms, including but not limited to those described below.

*Forward-looking statements*

*This Annual Report on Form 10-K, including this Management’s Discussion and Analysis of Financial Condition and Results of Operations, contains statements that are forward-looking statements within the meaning of the federal securities laws and as such are intended to be covered by the safe harbor for "forward-looking statements" provided by the Private Securities Litigation Reform Act of 1995.

These forward-looking statements could include, among other things, DaVita's response to and the expected future impacts of the novel coronavirus (COVID-19), including statements about our balance sheet and liquidity, our expenses and expense offsets, revenues, billings and collections, potential need, ability or willingness to use any funds under government relief programs, availability or cost of supplies, treatment volumes, mix expectation, such as the percentage or number of patients under commercial insurance, the availability and administration of COVID-19 vaccines, and overall impact on our patients and teammates, as well as other statements regarding our future operations, financial condition and prospects, expenses, strategic initiatives, government and commercial payment rates, expectations related to value-based care and Medicare Advantage plan enrollment and our ongoing stock repurchase program.

All statements in this report, other than statements of historical fact, are forward-looking statements.

Without limiting the foregoing, statements including the words "expect," "intend," "will," "could," "plan," "anticipate," "believe," "forecast," "guidance," "outlook," "goals," and similar expressions are intended to identify forward-looking statements.

These forward-looking statements are based on DaVita's current expectations and are based solely on information available as of the date of this report.

DaVita undertakes no obligation to publicly update or revise any forward-looking statements, whether as a result of changed circumstances, new information, future events or otherwise, except as may be required by law.

Actual future events and results could differ materially from any forward-looking statements due to numerous factors that involve substantial known and unknown risks and uncertainties.

These risks and uncertainties include, among other things:*

*•the continuing impact of the dynamic and evolving COVID-19 pandemic, including, without limitation, on our patients, teammates, physician partners, suppliers, business, operations, reputation, financial condition and results of operations; the government’s response to the COVID-19 pandemic; the availability, acceptance, impact and efficacy of COVID-19 treatments, therapies and vaccines; further spread or resurgence of the virus, including as a result of the emergence of new strains of the virus; the continuing impact of the pandemic on our revenue and non-acquired growth due to lower treatment volumes; the consequences of an extended economic downturn resulting from the impacts of COVID-19, such as a potential negative impact on our commercial mix, which may persist even after the pandemic subsides; and continuing COVID-19-related costs, such as costs to procure equipment and clinical supplies and higher salary and wage expense.

The aforementioned risks and uncertainties may also have the effect of heightening many of the other risks and uncertainties discussed below;*

*•the concentration of profits generated by higher-paying commercial payor plans for which there is continued downward pressure on average realized payment rates, and a reduction in the number or percentage of our patients under such plans, including, without limitation, as a result of restrictions or prohibitions on the use and/or availability of charitable premium assistance, which may result in the loss of revenues or patients, or our making incorrect assumptions about how our patients will respond to any change in financial assistance from charitable organizations;*

*•noncompliance by us or our business associates with any privacy or security laws or any security breach by us or a third party involving the misappropriation, loss or other unauthorized use or disclosure of confidential information;*

*•the extent to which the ongoing implementation of healthcare reform, or changes in or new legislation, regulations or guidance, enforcement thereof or related litigation result in a reduction in coverage or reimbursement rates for our services, a reduction in the number of patients enrolled in higher-paying commercial plans or that are enrolled in or select Medicare Advantage plans or other material impacts to our business; or our making incorrect assumptions about how our patients will respond to any such developments;*

- *a reduction in government payment rates under the Medicare End Stage Renal Disease program or other government-based programs and the impact of the Medicare Advantage benchmark structure;*

*•risks arising from potential changes in laws, regulations or requirements applicable to us, such as potential and proposed federal and/or state legislation, regulation, ballot, executive action or other initiatives, including those related to healthcare and/or labor matters, such as AB 290 in California;*

*•the impact of the political environment and related developments on the current healthcare marketplace and on our business, including with respect to the future of the Affordable Care Act, the exchanges and many other core aspects*

*of the current healthcare marketplace, as well as the composition of the U.S. Supreme Court and the new presidential administration and congressional majority;*

*•our ability to successfully implement our strategies with respect to home-based dialysis, value-based care and/or integrated kidney care, including maintaining our existing business and further developing our capabilities in a complex and highly regulated environment;*

- *changes in pharmaceutical practice patterns, reimbursement and payment policies and processes, or pharmaceutical pricing, including with respect to hypoxia inducible factors;*

- *legal and compliance risks, such as our continued compliance with complex government regulations;*

- *continued increased competition from dialysis providers and others, and other potential marketplace changes;*

- *our ability to maintain contracts with physician medical directors, changing affiliation models for physicians, and the emergence of new models of care introduced by the government or private sector that may erode our patient base and reimbursement rates, such as accountable care organizations, independent practice associations and integrated delivery systems;*

- *our ability to complete acquisitions, mergers or dispositions that we might announce or be considering, on terms favorable to us or at all, or to integrate and successfully operate any business we may acquire or have acquired, or to successfully expand our operations and services in markets outside the United States, or to businesses outside of dialysis;*

*•the variability of our cash flows, including without limitation any extended billing or collections cycles; the risk that we may not be able to generate or access sufficient cash in the future to service our indebtedness or to fund our other liquidity needs; and the risk that we may not be able to refinance our indebtedness as it becomes due, on terms favorable to us or at all;*

- *factors that may impact our ability to repurchase stock under our stock repurchase program and the timing of any such stock repurchases, as well as our use of a considerable amount of available funds to repurchase stock;*

- *risks arising from the use of accounting estimates, judgments and interpretations in our financial statements;*

- *impairment of our goodwill, investments or other assets; and*

- *uncertainties associated with the other risk factors set forth in Part I, Item 1A.

of this Annual Report on Form 10-K, and the other risks and uncertainties discussed in any subsequent reports that we file or furnish with the SEC from time to time.*

*The following should be read in conjunction with our consolidated financial statements.*

Company overview

Our principal business is to provide dialysis and related lab services to patients in the United States, which we refer to as our U.S. dialysis business.

We also operate various ancillary services and strategic initiatives including our international operations, which we collectively refer to as our ancillary services, as well as our corporate administrative support.

Our U.S. dialysis business is a leading provider of kidney dialysis services in the U.S. for patients suffering from chronic kidney failure, also known as end stage renal disease (ESRD) or end stage kidney disease (ESKD).

On June 19, 2019, we completed the sale of our DaVita Medical Group (DMG) business to Collaborative Care Holdings, LLC, a subsidiary of UnitedHealth Group Inc. As a result of this transaction, DMG's results of operations have been reported as discontinued operations for all periods presented and DMG is not included below in this Management's Discussion and Analysis.

Notwithstanding the challenges of responding to the novel coronavirus pandemic (COVID-19), our year-over-year overall financial performance in 2020 benefited from increased revenue, which was primarily due to higher average revenue per treatment in our U.S. dialysis business as well as acquired growth in our international business.

This was partially offset by increases in labor costs (both operating and overhead), lower margin on calcimimetics, increases in advocacy costs, and increased costs driven by the emergence of COVID-19, including increased costs related to compensation and medical supplies.

Drivers of our financial performance in 2020 included the following:

- improved key clinical outcomes in our U.S. dialysis business, including our recognition as an industry leader for the eighth consecutive year in CMS’ Quality Incentive Program and for the last seven years under the CMS Five-Star Quality Rating system;

Interest rate sensitivity

The tables below provide information about our financial instruments that are sensitive to changes in interest rates.

The first table below presents principal repayments and current weighted average interest rates on our debt obligations as of December 31, 2020.

The variable rates presented reflect the weighted average LIBOR rates in effect for all debt tranches plus interest rate margins in effect as of December 31, 2020.

The Term Loan A interest rate margin in effect at December 31, 2020, was 1.50%.

At December 31, 2020, the Term Loan B-1 interest rate margin in effect was 1.75%.

At December 31, 2020, we had an outstanding balance on our revolving line of credit bearing interest at an Alternate Base Rate (the Prime Rate) plus 0.50%.

On January 6, 2021 our revolving line of credit rate was converted to a LIBOR-based rate of LIBOR plus 1.50%.

The interest rates in effect on our Term Loan A and revolving line of credit are subject to adjustment depending upon changes in our leverage ratio.

| | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | |

| --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- |

| | | | Expected maturity date | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | Average interest rate | | | | | | Fair value(1) | | |

| | | | 2021 | | | | | | 2022 | | | | | | 2023 | | | | | | 2024 | | | | | | 2025 | | | | | | Thereafter | | | | | | Total | | | | | | | | | | | | | | |

| | | | (dollars in millions) | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | |

| Long term debt: | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | |

| Fixed rate | | | $ | 31 | | | | | $ | 34 | | | | | $ | 48 | | | | | $ | 29 | | | | | $ | 33 | | | | | $ | 3,448 | | | | | $ | 3,623 | | | | | 4.32 | | % | | | | $ | 3,481 | |

| Variable rate | | | $ | 138 | | | | | $ | 136 | | | | | $ | 179 | | | | | $ | 1,468 | | | | | $ | 36 | | | | | $ | 2,584 | | | | | $ | 4,541 | | | | | 2.05 | | % | | | | $ | 4,518 | |

(1)Represents the fair value of our long-term debt excluding financing leases.

| | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | |

| --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- |

| | | | Notional amount | | | | | | Contract maturity date | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | Receive variable | | | | | | Fair value | | |

| | | | | | | 2021 | | | | | | 2022 | | | | | | 2023 | | | | | | 2024 | | | | | | 2025 | | | | | | | | | | | | | | | | | |

| | | | (dollars in millions) | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | |

| 2019 cap agreements | | | $ | 3,500 | | | | | $ | — | | | | | $ | — | | | | | $ | — | | | | | $ | 3,500 | | | | | $ | — | | | | | LIBOR above 2.0% | | | | | | $ | 2.7 | |

For a further discussion of our debt, see Note 13 to our consolidated financial statements at Part II Item 15, "*Exhibits, Financial Statement Schedules" – Note 13 – "Long-term debt*" as referred from Part II Item 8, "*Financial Statements and Supplementary Data.*"

We believe that our cash flow from operations and other sources of liquidity, including from amounts available under our current credit facilities and our access to the capital markets, will be sufficient to fund our scheduled debt service under the terms of our debt agreements and other obligations for the foreseeable future, including the next 12 months.

Our primary recurrent sources of liquidity are cash from operations and cash from borrowings.

One means of assessing exposure to debt-related interest rate changes is a duration-based analysis that measures the potential loss in net income resulting from a hypothetical increase in interest rates of 100 basis points across all variable rate maturities (referred to as a parallel shift in the yield curve).

Under this model, with all else constant, it is estimated that such an increase would have reduced net income by approximately $34.8 million, $32.4 million, and $37.8 million, net of tax, for the years ended December 31, 2020, 2019, and 2018, respectively.

*Exchange rate sensitivity*

While our business is predominantly conducted in the U.S., we have developing operations in ten other countries as well.

For financial reporting purposes, the U.S. dollar is our reporting currency.

However, the functional currencies of our operating businesses in other countries are typically those of the countries in which they operate.

Therefore, changes in the rate of exchange between the U.S. dollar and the local currencies in which our international operations are conducted affect our results of operations and financial position as reported in our consolidated financial statements.

We have consolidated the balance sheets of our non-U.S. dollar denominated operations into U.S. dollars at the exchange rates prevailing at the balance sheet dates and have translated their revenues and expense at average exchange rates during each period.

Additionally, our individual subsidiaries are exposed to transactional risks mainly resulting from intercompany transactions between and among subsidiaries with different functional currencies.

This exposes the subsidiaries to fluctuations in the rate of exchange between the invoicing or obligation currencies and the currency in which their local operations are conducted.

We evaluate our exposure to foreign exchange risk through the judgment of our international and corporate management teams.

Through 2020, our international operations have remained fairly small relative to the size of our consolidated financial statements, constituting approximately 9% of our consolidated assets as of December 31, 2020, with no single country constituting more than 3% of consolidated assets, and approximately 5% of our consolidated revenues for the year ended December 31, 2020.

In addition, our foreign currency translation (losses) gains were approximately (0.4)%, (1)%, and (3)% of our consolidated operating income for the years ended December 31, 2020, 2019 and 2018.

*Unless otherwise indicated in this Annual Report on Form 10-K “DaVita”, “the Company” “we”, “us”, “our” and other similar terms refer to DaVita Inc. and its consolidated subsidiaries.

Our annual report on Form 10-K, quarterly reports on Form 10-Q, current reports on Form 8-K and amendments to those reports filed or furnished pursuant to section 13(a) or 15(d) of the Securities Exchange Act of 1934, as amended, are made available free of charge through our website, located at* *http://www.davita.com, as soon as reasonably practicable after the reports are filed with or furnished to the Securities and Exchange Commission (SEC).

The SEC also maintains a website at* *http://www.sec.gov* *where these reports and other information about us can be obtained.

The contents of our website are not incorporated by reference into this report.*

Overview of DaVita Inc.

DaVita is a leading healthcare provider focused on transforming care delivery to improve quality of life for patients globally.

We are one of the largest providers of kidney care services in the U.S. and have been a leader in clinical quality and innovation for over 20 years.

DaVita is committed to bold, patient-centric care models, implementing the latest technologies and moving toward integrated care offerings.

Over the years, we have established a value-based culture with a philosophy of caring that is focused on both our patients and teammates.

This culture and philosophy fuel our continuous drive toward achieving our mission to be the provider, partner and employer of choice and fulfilling our vision to "build the greatest healthcare community the world has ever seen."

The loss of kidney function is normally irreversible.

Kidney failure is typically caused by Type I and Type II diabetes, hypertension, polycystic kidney disease, long-term autoimmune attack on the kidneys and prolonged urinary tract obstruction.

End stage renal disease or end stage kidney disease (ESRD or ESKD) is the stage of advanced kidney impairment that requires continued dialysis treatments or a kidney transplant to sustain life.

Dialysis is the removal of toxins, fluids and salt from the blood of patients by artificial means.

Patients suffering from ESRD generally require dialysis at least three times a week for the rest of their lives.

Our U.S. dialysis and related lab services (U.S. dialysis) business treats patients with chronic kidney failure and ESRD in the United States, and is our largest line of business.

As of December 31, 2020, we provided dialysis and administrative services and related laboratory services throughout the U.S. via a network of 2,816 outpatient dialysis centers in 46 states and the District of Columbia, serving a total of approximately 204,200 patients and provided hospital inpatient dialysis services in approximately 900 hospitals.

Our robust platform to deliver kidney care services also includes established nephrology and payor relationships as well as home programs.

In addition, as of December 31, 2020, we provided dialysis and administrative services to a total of 321 outpatient dialysis centers located in ten countries outside of the U.S., serving approximately 36,200 patients.

The Company also consists of our ancillary services and strategic initiatives, which include the aforementioned international operations (collectively, our ancillary services), as well as our corporate administrative support.

Our patient-centric care model leverages our platform of kidney care services to maximize patient choice in both models and modalities of care.

We believe that the flexibility we offer coupled with a focus on comprehensive kidney care supports our commitments to help improve clinical outcomes and quality of life for our patients.

For the eighth consecutive year, we are an industry leader in the Centers for Medicare & Medicaid Services’ (CMS) Quality Incentive Program (QIP), which promotes high quality services in outpatient dialysis facilities treating patients with ESRD.

We are also an industry leader for the seventh consecutive year under CMS’ Five-Star Quality Rating system, which rates eligible dialysis centers based on the quality of outcomes to help patients, their families, and caregivers make more informed decisions about where patients receive care.

According to the most recently collected data, we are an industry leader for the total number of patients in home-based dialysis services.

Our quality clinical outcomes are driven by our experienced and knowledgeable teammates.

We employ registered nurses, licensed practical or vocational nurses, patient care technicians, social workers, registered dietitians, biomedical technicians and other administrative and support teammates who strive to achieve superior clinical outcomes at our dialysis facilities.

In addition to our teammates at our dialysis facilities, as of December 31, 2020, our domestic Chief Medical Officer leads a team of 18 senior nephrologists in our physician leadership team as part of our domestic Office of the Chief Medical Officer (OCMO).

Our international Chief Medical Officer leads a team of 11 senior nephrologists in our physician leadership team as part of our international OCMO.

Our OCMO teammates represent a variety of academic, clinical practice, and clinical research backgrounds.

We also have a Physician Counsel that serves as an advisory body to senior management, which is composed of nine physicians with extensive experience in clinical practice and have seven Group Medical Directors as of December 31, 2020.

On June 19, 2019, we completed the sale of our DaVita Medical Group (DMG) business, a patient and physician-focused integrated healthcare delivery and management company, to Collaborative Care Holdings, LLC, a subsidiary of UnitedHealth Group Inc. As a result, the DMG business has been classified as discontinued operations and its results of operations are reported as discontinued operations for all periods presented in the consolidated financial statements included in this report.

For financial information about DMG, see Note 22 to the consolidated financial statements included in this report.

COVID-19 and its impact on our business

As a caregiving organization, we are exposed to and will continue to be impacted by the effects of the novel coronavirus (COVID-19) pandemic.

DaVita’s teammates include, among others, dialysis nurses, patient care technicians, social workers, dieticians and other caregivers who are on the front lines of the ongoing COVID-19 pandemic providing critical, life-sustaining care for our patients.

We are closely monitoring the impact on our business of the pandemic and the resulting economic environment, including the impact on our patients, teammates, physician partners, suppliers, vendors and business partners.

During this time of great challenge, our top priorities continue to be the health, safety and well-being of our patients, teammates and physician partners and helping to ensure that our patients have the ability to maintain continuity of care throughout this crisis, whether in the hospital, outpatient or home setting.

To that end, we have dedicated and continue to dedicate substantial resources in response to COVID-19, including the implementation of additional protocols in coordination with the Centers for Disease Control and Prevention (CDC) on infection control and clinical best practices to help safely maintain continuity of care for our patients and help protect our caregivers.

We also have been collaborating with the CDC, the U.S. Department of Health and Human Services (HHS), CMS, the American Society of Nephrology, and dialysis providers nationwide to help ensure that the dialysis community is able to support patients nationwide during this global health crisis.

The information required by this Part I, Item 3 is incorporated herein by reference to the information set forth under the caption “*Contingencies*” in Note 16 to the consolidated financial statements included in this report.

UNITED STATES

SECURITIES AND EXCHANGE COMMISSION

Washington, D.C. 20549

FORM 10-K

| | | | | | |

| --- | --- | --- | --- | --- | --- |

| ☒ | | | ANNUAL REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 | | |

For the Fiscal Year Ended December 31, 2020

or

| | | | | | |

| --- | --- | --- | --- | --- | --- |

| ☐ | | | TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 | | |

For the transition period from ___________ to ___________

Commission File Number: 1-14106


DAVITA INC.

(Exact name of registrant as specified in charter)

| | | | | | | | | |

| --- | --- | --- | --- | --- | --- | --- | --- | --- |

| Delaware | | | | | | 51-0354549 | | |

| (State of incorporation) | | | | | | (I.R.S. Employer Identification No.) | | |

| | | | | | | | | |

| --- | --- | --- | --- | --- | --- | --- | --- | --- |

| 2000 16th Street | | | | | | | | |

| Denver, | | | CO | | | 80202 | | |

Telephone number (720) 631-2100

Securities registered pursuant to Section 12(b) of the Act:

| | | | | | | | | | | | | | | |

| --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- |

| Title of each class: | | | | | | Trading symbol(s): | | | | | | Name of each exchange on which registered: | | |

| Common Stock, $0.001 par value | | | | | | DVA | | | | | | New York Stock Exchange | | |

Securities registered pursuant to Section 12(g) of the Act:

None

Indicate by check mark if the registrant is a well-known seasoned issuer, as defined in Rule 405 of the Securities Act.

Yes ☒ No ☐

Indicate by check mark if the registrant is not required to file reports pursuant to Section 13 or Section 15(d) of the Exchange Act.

Yes ☐ No ☒

Indicate by check mark whether the registrant (1) has filed all reports required to be filed by Section 13 or 15(d) of the Securities Exchange Act of 1934 during the preceding 12 months (or for such shorter period that the registrant was required to file such reports) and (2) has been subject to such filing requirements for the past 90 days.

Yes ☒ No

Indicate by check mark whether the registrant has submitted electronically every Interactive Data File required to be submitted pursuant to Rule 405 of Regulation S-T (§232.405 of this chapter) during the preceding 12 months (or for such shorter period that the registrant was required to submit such files).

None.

Our corporate headquarters are located in Denver, Colorado, consisting of one owned 240,000 square foot building and one leased 345,900 square foot location.

Our headquarters are occupied by teammates engaged in management, finance, marketing, strategy, legal, compliance and other administrative functions.

We lease five business offices located in California, Pennsylvania, Tennessee and Washington, as well as own one business office in Washington for our U.S. dialysis business.

Our laboratory is based in Florida where we operate our lab services out of one leased building.

We also lease other administrative offices in the U.S. and worldwide.

For our U.S. dialysis business we own the land and buildings for six outpatient dialysis centers.

We also own 21 properties for development, including operating outpatient dialysis centers and properties we hold for sale.

In addition, we lease a total of four owned properties to third-party tenants.

Our remaining outpatient dialysis centers are located on premises that we lease.

The majority of our leases for our U.S. dialysis business cover periods from five years to 20 years and typically contain renewal options of five years to ten years at the fair rental value at the time of renewal.

Our leases are generally subject to periodic consumer price index increases, or contain fixed escalation clauses.

Our outpatient dialysis centers range in size from approximately 1,000 to 33,000 square feet, with an average size of approximately 7,800 square feet.

Our international leases generally range from one to ten years.

Some of our outpatient dialysis centers are operating at or near capacity.

However, we believe that we have adequate capacity within most of our existing dialysis centers to accommodate additional patient volume through increased hours and/or days of operation, or, if additional space is available within an existing facility, by adding dialysis stations.

We can usually relocate existing centers to larger facilities or open new centers if existing centers reach capacity.

With respect to relocating centers or building new centers, we believe that we can generally lease space at economically reasonable rates in the areas planned for each of these centers, although there can be no assurances in this regard.

Expansion of existing centers or relocation of our dialysis centers is subject to review for compliance with conditions relating to participation in the Medicare ESRD program, among other things.

In states that require a certificate of need or center license, additional approvals would generally be necessary for expansion or relocation.

Not applicable.

PART II

Our common stock is traded on the New York Stock Exchange under the symbol DVA.

The closing price of our common stock on January 29, 2021 was $117.37 per share.

According to Computershare, our registrar and transfer agent, as of January 29, 2021, there were 7,594 holders of record of our common stock.

This figure does not include the indeterminate number of beneficial holders whose shares are held of record by brokerage firms and clearing agencies.

Our initial public offering was in 1994, and we have not declared or paid cash dividends to holders of our common stock since going public.

We have no current plans to pay cash dividends and there are certain limitations on our ability to pay dividends under the terms of our senior secured credit facilities.

See “*Liquidity and capital resources*” under Item 7.

"*Management’s Discussion and Analysis of Financial Condition and Results of Operations*” and the notes to the consolidated financial statements.

*Stock Repurchases*

The following table summarizes our repurchases of our common stock during the fourth quarter of 2020:

| | | | | | | | | | | | | | | | | | | | | | | | |

| --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- |

| Period | | | Total number of shares purchased | | | | | | Average price paid per share | | | | | | Total number of shares purchased as part of publicly announced plans or programs | | | | | | Approximate dollar value of shares that may yet be purchased under the plans or programs | | |

| | | | (dollars and shares in thousands, except per share data) | | | | | | | | | | | | | | | | | | | | |

| October 1-31, 2020 | | | 1,828 | | | | | | $ | 87.96 | | | | | 1,828 | | | | | | $ | 515,926 | |

| November 1-30, 2020 | | | 1,149 | | | | | | 105.54 | | | | | | 1,149 | | | | | | $ | 394,628 | |

| December 1-31, 2020 | | | 1,216 | | | | | | 111.91 | | | | | | 1,216 | | | | | | $ | 1,929,955 | |

| Total | | | 4,193 | | | | | | $ | 99.73 | | | | | 4,193 | | | | | | | | |

The following table summarizes our repurchases of our common stock during 2020:

| | | | | | | | | | | | | | | | | | | | | | | | |

| --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- |

| Period | | | Total number of shares purchased | | | | | | Average price paid per share | | | | | | Total number of shares purchased as part of publicly announced plans or programs | | | | | | Approximate dollar value of shares that may yet be purchased under the plans or programs | | |

| | | | (dollars and shares in thousands, except per share data) | | | | | | | | | | | | | | | | | | | | |

| January 1 - March 31, 2020 | | | 4,052 | | | | | | $ | 74.81 | | | | | 4,052 | | | | | | $ | 1,400,356 | |

| April 1 - June 30, 2020 | | | — | | | | | | — | | | | | | — | | | | | | $ | 1,400,356 | |

| July 1 - September 30, 2020(1) | | | 8,232 | | | | | | 88.13 | | | | | | 8,232 | | | | | | $ | 676,709 | |

| October 1 - December 31, 2020 | | | 4,193 | | | | | | 99.73 | | | | | | 4,193 | | | | | | $ | 1,929,955 | |

| Total | | | 16,477 | | | | | | $ | 87.80 | | | | | 16,477 | | | | | | | | |

(1)The total number of shares purchased and the aggregate amount paid for shares repurchased include shares repurchased pursuant to our modified Dutch auction tender offer at a clearing price of $88.00 per share plus related fees and expenses of $2.5 million.

Effective as of the close of business on November 4, 2019, the Board terminated all remaining prior share repurchase authorizations available to us and approved a new share repurchase authorization of $2.0 billion.

Effective on December 10, 2020, the Board terminated all remaining prior share repurchase authorizations available to us under the aforementioned November 4, 2019 authorization and approved a new share repurchase authorization of $2.0 billion.

We are authorized to make purchases from time to time in the open market or in privately negotiated transactions, including without limitation, through accelerated share repurchase transactions, derivative transactions, tender offers, Rule 10b5-1 plans or any combination of the foregoing, depending upon market conditions and other considerations.

As of February 10, 2021, we have a total of $1.807 billion available under the current repurchase authorization for additional share repurchases.

Although this share repurchase authorization does not have an expiration date, we remain subject to share repurchase limitations, including under the terms of our senior secured credit facilities.

The following financial and operating data should be read in conjunction with Item 7.

"*Management’s Discussion and Analysis of Financial Condition and Results of Operations*” and our consolidated financial statements filed as part of this report.

The following table presents selected consolidated financial and operating data for the periods indicated:

| | | | | | | | | | | | | | | | | | | | | | | | | | | | | | |

| --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- |

| | | | Year ended December 31, | | | | | | | | | | | | | | | | | | | | | | | | | | |

| | | | 2020 | | | | | | 2019 | | | | | | 2018 | | | | | | 2017 | | | | | | 2016 | | |

| | | | (dollars and shares in thousands, except per share data) | | | | | | | | | | | | | | | | | | | | | | | | | | |

| Income statement data: | | | | | | | | | | | | | | | | | | | | | | | | | | | | | |

| Total revenues(1) | | | $ | 11,550,604 | | | | | $ | 11,388,479 | | | | | $ | 11,404,851 | | | | | $ | 10,876,634 | | | | | $ | 10,707,467 | |

| Operating expenses and charges(2) | | | 9,855,968 | | | | | | 9,745,162 | | | | | | 9,879,027 | | | | | | 9,063,879 | | | | | | 8,677,757 | | |

| Operating income | | | 1,694,636 | | | | | | 1,643,317 | | | | | | 1,525,824 | | | | | | 1,812,755 | | | | | | 2,029,710 | | |

| Debt expense | | | (304,111) | | | | | | (443,824) | | | | | | (487,435) | | | | | | (430,634) | | | | | | (414,116) | | |

| Debt prepayment, refinancing and redemption charges | | | (89,022) | | | | | | (33,402) | | | | | | — | | | | | | — | | | | | | — | | |

| Other income, net | | | 16,759 | | | | | | 29,348 | | | | | | 10,089 | | | | | | 17,665 | | | | | | 7,511 | | |

| Income from continuing operations before income taxes | | | 1,318,262 | | | | | | 1,195,439 | | | | | | 1,048,478 | | | | | | 1,399,786 | | | | | | 1,623,105 | | |

| Income tax expense(3) | | | 313,932 | | | | | | 279,628 | | | | | | 258,400 | | | | | | 323,859 | | | | | | 431,761 | | |

| Net income from continuing operations | | | 1,004,330 | | | | | | 915,811 | | | | | | 790,078 | | | | | | 1,075,927 | | | | | | 1,191,344 | | |

| Net (loss) income from discontinued operations, net of tax(4) | | | (9,653) | | | | | | 105,483 | | | | | | (457,038) | | | | | | (245,372) | | | | | | (158,262) | | |

| Net income | | | 994,677 | | | | | | 1,021,294 | | | | | | 333,040 | | | | | | 830,555 | | | | | | 1,033,082 | | |

| Less: Net income attributable to noncontrolling interests | | | (221,035) | | | | | | (210,313) | | | | | | (173,646) | | | | | | (166,937) | | | | | | (153,208) | | |

| Net income attributable to DaVita Inc. | | | $ | 773,642 | | | | | $ | 810,981 | | | | | $ | 159,394 | | | | | $ | 663,618 | | | | | $ | 879,874 | |

| | | | | | | | | | | | | | | | | | | | | | | | | | | | | | |

| Earnings per share attributable to DaVita Inc.: | | | | | | | | | | | | | | | | | | | | | | | | | | | | | |

| Basic income from continuing operations(5) | | | $ | 6.54 | | | | | $ | 4.61 | | | | | $ | 3.66 | | | | | $ | 4.78 | | | | | $ | 5.12 | |

| Diluted income from continuing operations(5) | | | $ | 6.39 | | | | | $ | 4.60 | | | | | $ | 3.62 | | | | | $ | 4.71 | | | | | $ | 5.04 | |

| | | | | | | | | | | | | | | | | | | | | | | | | | | | | | |

| Weighted average shares for earnings per share(5): | | | | | | | | | | | | | | | | | | | | | | | | | | | | | |

| Basic shares | | | 119,797 | | | | | | 153,181 | | | | | | 170,786 | | | | | | 188,626 | | | | | | 201,641 | | |

| Diluted shares | | | 122,623 | | | | | | 153,812 | | | | | | 172,365 | | | | | | 191,349 | | | | | | 204,905 | | |

| | | | | | | | | | | | | | | | | | | | | | | | | | | | | | |

| Balance sheet data (as of period end): | | | | | | | | | | | | | | | | | | | | | | | | | | | | | |

| Working capital | | | $ | 672,581 | | | | | $ | 1,318,072 | | | | | $ | 3,532,998 | | | | | $ | 5,703,181 | | | | | $ | 1,283,784 | |

| Total assets | | | $ | 16,988,516 | | | | | $ | 17,311,394 | | | | | $ | 19,110,252 | | | | | $ | 18,974,536 | | | | | $ | 18,755,776 | |

| Long-term debt | | | $ | 7,917,263 | | | | | $ | 7,977,526 | | | | | $ | 8,172,847 | | | | | $ | 9,158,018 | | | | | $ | 8,944,676 | |

| Total DaVita Inc. shareholders' equity(5) | | | $ | 1,383,566 | | | | | $ | 2,133,409 | | | | | $ | 3,703,442 | | | | | $ | 4,690,029 | | | | | $ | 4,648,047 | |

(1)On January 1, 2018, we adopted *Revenue from Contracts with Customers* (Topic 606) using the cumulative effect method for those contracts that were not substantially completed as of January 1, 2018.

See Notes 1 and 2 of the consolidated financial statements for further discussion of our adoption of Topic 606.

(2)The following table summarizes losses (gains) on changes in ownership interest, net, accruals for legal matters, impairment charges, restructuring charges and gain on settlement included in operating expenses and charges:

| | | | | | | | | | | | | | | | | | | | | | | | | | | | | | |

See the Index to Financial Statements and Index to Financial Statement Schedules included at Item 15, "*Exhibits, Financial Statement Schedules.*”

None.

Management has established and maintains disclosure controls and procedures designed to ensure that information required to be disclosed in the reports that it files or submits pursuant to the Securities Exchange Act of 1934 (Exchange Act) as amended is recorded, processed, summarized and reported within the time periods specified in the SEC’s rules and forms, and that such information is accumulated and communicated to our management including our Chief Executive Officer ("CEO") and Chief Financial Officer ("CFO") as appropriate to allow for timely decisions regarding required disclosures.

At the end of the period covered by this report, we carried out an evaluation, under the supervision and with the participation of our CEO and CFO, of the effectiveness of the design and operation of the Company's disclosure controls and procedures in accordance with the Exchange Act requirements as of December 31, 2020.

Based upon that evaluation, the CEO and CFO concluded that the Company's disclosure controls and procedures were effective as required by the Exchange Act as of such date for our Exchange Act reports, including this report.

Management recognizes that these controls and procedures can provide only reasonable assurance of desired outcomes, and that estimates and judgments are still inherent in the process of maintaining effective controls and procedures.

There was no change in the Company's internal control over financial reporting that was identified during the evaluation that occurred during the fourth fiscal quarter of 2020 that has materially affected, or is reasonably likely to materially affect, the Company's internal control over financial reporting.

None.

PART III

We intend to disclose any amendments or waivers to the Code of Ethics applicable to our principal executive officer, principal financial officer, principal accounting officer or controller or persons performing similar functions, on our website located at http://www.davita.com.

In 2002, we adopted a Corporate Governance Code of Ethics that applies to our principal executive officer, principal financial officer, principal accounting officer or controller, and to all of our financial accounting and legal professionals who are directly or indirectly involved in the preparation, reporting and fair presentation of our financial statements and Exchange Act reports.

The Code of Ethics is posted on our website, located at http://www.davita.com.

We also maintain a Corporate Code of Conduct that applies to all of our employees, officers and directors, which is posted on our website.

Under our Corporate Governance Guidelines all Board Committees including the Audit Committee, Nominating and Governance Committee and the Compensation Committee, which are comprised solely of independent directors as defined within the listing standards of the New York Stock Exchange, have written charters that outline the committee’s purpose, goals, membership requirements and responsibilities.

These charters are regularly reviewed and updated as necessary by our Board of Directors.

All Board Committee charters as well as the Corporate Governance Guidelines are posted on our website located at http://www.davita.com.

The other information required to be disclosed by this item will appear in, and is incorporated by reference from, the sections entitled “*Proposal 1 Election of Directors*”, “*Corporate Governance*”, and “*Security Ownership of Certain Beneficial Owners and Management*” to be included in our definitive proxy statement relating to our 2021 annual stockholder meeting.

The information required by this item will appear in, and is incorporated by reference from, the sections entitled "*Executive Compensation*", "*Pay Ratio Disclosure*", "*Compensation of Directors*" and "*Compensation Committee Interlocks and Insider Participation*" included in our definitive proxy statement relating to our 2021 annual stockholder meeting.

The information required by Item 407(e)(5) of Regulation S-K will appear in and is incorporated by reference from the section entitled “*Compensation Committee Report*” to be included in our definitive proxy statement relating to our 2021 annual stockholder meeting; however, this information shall not be deemed to be filed.

The following table provides information about our common stock that may be issued upon the exercise of stock-settled stock appreciation rights, restricted stock units and other rights under all of our existing equity compensation plans as of December 31, 2020, which consist of our 2020 Incentive Award Plan, 2011 Incentive Award Plan and our Employee Stock Purchase Plan.

The material terms of these plans are described in Note 18 to the consolidated financial statements.

| | | | | | | | | | | | | | | | | | | | | | | | | | | |

| --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- |

| Plan category (shares in thousands) | | | | | | Number of shares to be issued upon exercise of outstanding options, warrants and rights(1) | | | | | | Weighted average exercise price of outstanding options, warrants and rights(2) | | | | | | Number of shares remaining available for future issuance under equity compensation plans (excluding securities reflected in column (a)) | | | | | | Total of shares reflected in columns (a) and (c) | | |

| | | | | | | (a) | | | | | | (b) | | | | | | (c) | | | | | | (d) | | |

| Equity compensation plans approved by shareholders | | | | | | 12,167 | | | | | | $ | 63.64 | | | | | 14,263 | | | | | | 26,430 | | |

| Equity compensation plans not requiring shareholder approval | | | | | | — | | | | | | — | | | | | | — | | | | | | — | | |

| Total | | | | | | 12,167 | | | | | | $ | 63.64 | | | | | 14,263 | | | | | | 26,430 | | |

1.Includes 1,092 shares of common stock reserved for issuance in connection with performance share units at the maximum number of shares issuable thereunder.

2.This weighted average excludes full value awards such as restricted stock units and performance share units.

Other information required to be disclosed by Item 12 will appear in, and is incorporated by reference from, the section entitled “*Security Ownership of Certain Beneficial Owners and Management*” to be included in our definitive proxy statement relating to our 2021 annual stockholder meeting.

The information required by this item will appear in, and is incorporated by reference from, the section entitled “*Certain Relationships and Related Transactions*” and the section entitled “*Corporate Governance*” to be included in our definitive proxy statement relating to our 2021 annual stockholder meeting.

The information required by this item will appear in, and is incorporated by reference from, the section entitled “*Proposal 2 Ratification of the Appointment of our Independent Registered Public Accounting Firm*” to be included in our definitive proxy statement relating to our 2021 annual stockholder meeting.

PART IV

(a) Documents filed as part of this Report:

*(1) Index to Financial Statements:*

| | | | | | |

| --- | --- | --- | --- | --- | --- |

| | | | Page | | |

| [Management’s Report on Internal Control Over Financial Reporting](#i878840fee65247deaca27d2dd6a8246f_163) | | | [F-1](#i878840fee65247deaca27d2dd6a8246f_163) | | |

| | | | | | |

| [Report of Independent Registered Public Accounting Firm](#i878840fee65247deaca27d2dd6a8246f_166) | | | [F-2](#i878840fee65247deaca27d2dd6a8246f_166) | | |

| | | | | | |

| [Report of Independent Registered Public Accounting Firm](#i878840fee65247deaca27d2dd6a8246f_169) | | | [F-5](#i878840fee65247deaca27d2dd6a8246f_169) | | |

| | | | | | |

| [Consolidated Statements of Income for the years ended December 31, 2020, 2019, and 2018](#i878840fee65247deaca27d2dd6a8246f_172) | | | [F-6](#i878840fee65247deaca27d2dd6a8246f_172) | | |

| | | | | | |

| [Consolidated Statements of Comprehensive Income for the years ended December 31, 2020, 2019, and 2018](#i878840fee65247deaca27d2dd6a8246f_175) | | | [F-7](#i878840fee65247deaca27d2dd6a8246f_175) | | |

| | | | | | |

| [Consolidated Balance Sheets as of December 31, 2020, and 2019](#i878840fee65247deaca27d2dd6a8246f_178) | | | [F-8](#i878840fee65247deaca27d2dd6a8246f_178) | | |

| | | | | | |

| [Consolidated Statements of Cash Flow for the years ended December 31, 2020, 2019, and 2018](#i878840fee65247deaca27d2dd6a8246f_184) | | | [F-9](#i878840fee65247deaca27d2dd6a8246f_184) | | |

| | | | | | |

| [Consolidated Statements of Equity for the years ended December 31, 2020, 2019, and 2018](#i878840fee65247deaca27d2dd6a8246f_187) | | | [F-10](#i878840fee65247deaca27d2dd6a8246f_187) | | |

| | | | | | |

| [Notes to Consolidated Financial Statements](#i878840fee65247deaca27d2dd6a8246f_190) | | | [F-12](#i878840fee65247deaca27d2dd6a8246f_190) | | |

*(2) Index to Financial Statement Schedules:*

| | | | | | |

| --- | --- | --- | --- | --- | --- |

| [Schedule II—Valuation and Qualifying Accounts](#i878840fee65247deaca27d2dd6a8246f_319) | | | [S-](#i878840fee65247deaca27d2dd6a8246f_319)3 | | |

*(3) Exhibits*

The information required by this Item is set forth in the Exhibit Index that precedes the signature pages of this Annual Report on Form 10-K.

None.

DAVITA INC.

MANAGEMENT’S REPORT ON INTERNAL CONTROL OVER FINANCIAL REPORTING

Management is responsible for establishing and maintaining an adequate system of internal control over financial reporting designed to provide reasonable assurance regarding the reliability of financial reporting and the preparation of financial statements for external purposes in accordance with U.S. generally accepted accounting principles and which includes those policies and procedures that (i) pertain to the maintenance of records that, in reasonable detail, accurately and fairly reflect the transactions and dispositions of the assets of the Company; (ii) provide reasonable assurance that transactions are recorded as necessary to permit preparation of financial statements in accordance with U.S. generally accepted accounting principles, and that receipts and expenditures of the Company are being made only in accordance with authorizations of management and directors of the Company; and (iii) provide reasonable assurance regarding prevention or timely detection of unauthorized acquisition, use, or disposition of the Company’s assets that could have a material effect on the financial statements.

During the last fiscal year, the Company conducted an evaluation, under the oversight of the Chief Executive Officer and Chief Financial Officer, of the effectiveness of the design and operation of the Company’s internal control over financial reporting.

This evaluation was completed based on the criteria established in the report titled “*Internal Control—Integrated Framework (2013)*” issued by the Committee of Sponsoring Organizations of the Treadway Commission (COSO).

Based upon our evaluation under the COSO framework, we have concluded that the Company’s internal control over financial reporting was effective as of December 31, 2020.

The Company’s independent registered public accounting firm, KPMG LLP, has issued an attestation report on the Company’s internal control over financial reporting, which report is included in this Annual Report.

F-1

Report of Independent Registered Public Accounting Firm

To the Stockholders and Board of Directors

DaVita Inc.:

*Opinion on the Consolidated* *Financial Statements*

We have audited the accompanying consolidated balance sheets of DaVita Inc. and subsidiaries (the Company) as of December 31, 2020 and 2019, the related consolidated statements of income, comprehensive income, equity, and cash flow for each of the years in the three-year period ended December 31, 2020, and the related notes and financial statement Schedule II – Valuation and Qualifying Accounts (collectively, the consolidated financial statements).

In our opinion, the consolidated financial statements present fairly, in all material respects, the financial position of the Company as of December 31, 2020 and 2019, and the results of its operations and its cash flows for each of the years in the three-year period ended December 31, 2020, in conformity with U.S. generally accepted accounting principles.

We also have audited, in accordance with the standards of the Public Company Accounting Oversight Board (United States) (PCAOB), the Company’s internal control over financial reporting as of December 31, 2020, based on criteria established in *Internal Control – Integrated Framework (2013)* issued by the Committee of Sponsoring Organizations of the Treadway Commission, and our report dated February 12, 2021 expressed an unqualified opinion on the effectiveness of the Company’s internal control over financial reporting.

*Change in Accounting Principle*

As discussed in Note 14 to the consolidated financial statements, the Company has changed its method of accounting for leases as of January 1, 2019 due to the adoption of the Financial Accounting Standards Board’s Accounting Standards Codification Topic 842 *Leases*.

*Basis for Opinion*

These consolidated financial statements are the responsibility of the Company’s management.

Our responsibility is to express an opinion on these consolidated financial statements based on our audits.

We are a public accounting firm registered with the PCAOB and are required to be independent with respect to the Company in accordance with the U.S. federal securities laws and the applicable rules and regulations of the Securities and Exchange Commission and the PCAOB.

We conducted our audits in accordance with the standards of the PCAOB.

Those standards require that we plan and perform the audit to obtain reasonable assurance about whether the consolidated financial statements are free of material misstatement, whether due to error or fraud.

Our audits included performing procedures to assess the risks of material misstatement of the consolidated financial statements, whether due to error or fraud, and performing procedures that respond to those risks.

Such procedures included examining, on a test basis, evidence regarding the amounts and disclosures in the consolidated financial statements.

Our audits also included evaluating the accounting principles used and significant estimates made by management, as well as evaluating the overall presentation of the consolidated financial statements.

We believe that our audits provide a reasonable basis for our opinion.

*Critical Audit Matters*

The critical audit matters communicated below are matters arising from the current period audit of the consolidated financial statements that were communicated or required to be communicated to the audit committee and that: (1) relate to accounts or disclosures that are material to the consolidated financial statements and (2) involved our especially challenging, subjective, or complex judgments.

The communication of critical audit matters does not alter in any way our opinion on the consolidated financial statements, taken as a whole, and we are not, by communicating the critical audit matters below, providing separate opinions on the critical audit matters or on the accounts or disclosures to which they relate.

*U.S. dialysis patient service revenue recognition*

As discussed in Notes 1 and 2 to the consolidated financial statements, the Company recognized $10,619 million in U.S. dialysis patient service revenue for the year ended December 31, 2020.

There are uncertainties associated with estimating U.S. dialysis patient service revenue, which generally take several years to resolve.

As these estimates are refined over time, both positive and negative adjustments are recognized in the current period.

F-2

We identified the evaluation of the recognition of the transaction price the Company expects to collect as a result of satisfying its performance obligations related to U.S. dialysis patient service revenue as a critical audit matter because it involves estimation that requires complex auditor judgment.

The key assumptions and inputs used to estimate the transaction price relate to ongoing insurance coverage changes, differing interpretations of contract coverage, determination of applicable primary and secondary coverage, coordination of benefits, and varying patient characteristics impacting Medicare reimbursements.

Changes to the key assumptions and inputs used in the application of the methodology may have a significant effect on the Company’s determination of the estimate.

The following are the primary procedures we performed to address this critical audit matter.

UNITED STATES

SECURITIES AND EXCHANGE COMMISSION

Washington, D.C. 20549

FORM 10-K

| | |

| --- | --- |

| | |

| ☒ | ANNUAL REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 |

For the Fiscal Year Ended December 31, 2019

or

| | |

| --- | --- |

| | |

| ☐ | TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 |

For the transition period from ___________ to ___________

Commission File Number: 1-14106


DAVITA INC.

(Exact name of registrant as specified in charter)

| | | |

| --- | --- | --- |

| | | |

| Delaware | | 51-0354549 |

| (State of incorporation) | | (I.R.S. Employer Identification No.) |

| | | |

| --- | --- | --- |

| | | |

| 2000 16th Street | | |

| Denver, | CO | 80202 |

Telephone number (720) 631-2100

Securities registered pursuant to Section 12(b) of the Act:

| | | | | |

| --- | --- | --- | --- | --- |

| | | | | |

| Title of each class: | | Trading symbol(s): | | Name of each exchange on which registered: |

| Common Stock, $0.001 par value | | DVA | | New York Stock Exchange |

Securities registered pursuant to Section 12(g) of the Act:

None

Indicate by check mark if the registrant is a well-known seasoned issuer, as defined in Rule 405 of the Securities Act.

Yes ☒ No ☐